+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 29 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

This research aims to compare two formulations of Tamsulosin hydrochloride 0.4 mg prolonged-release tablets to evaluate their bioequivalence and safety in healthy adult male volunteers. The study focuses on assessing how similarly the test medication from Synthon Hispania SL, Spain and the reference drug Omnic Ocas4 by Astellas Pharma Europe B.V., the Netherlands behave in the body when taken as a single dose under fasting conditions. This is a Phase I study involving healthy men aged 18 to 45 years. Participants will receive a single dose of either the test or reference Tamsulosin tablet with 240 ml of water while fasting. The study design includes a randomized, open-label, two-treatment, two-period, two-sequence crossover format, meaning each participant will receive both medications in different periods to allow direct comparison. The tablets differ in formulation one is a prolonged-release tablet and the other is a prolonged-release film-coated tablet. During the study, participants will undergo clinical, laboratory, and instrumental examinations to confirm health status and monitor effects. The primary outcomes measured include the maximum concentration Cmax and area under the curve AUC over specific timeframes to assess drug absorption and exposure. Secondary outcomes include various pharmacokinetic parameters such as time to maximum concentration Tmax and half-life t 12. The study lasts approximately 72 hours per dosing period with safety and adherence closely monitored by the research team.

Age: 18Years - 45YearsMALEPhase 1
1 location
S

Actively Recruiting

Researchers are evaluating invobenitug, also known as procizumab, in people with cardiogenic shock CS, a serious condition where the heart cannot pump enough blood to vital organs. This Phase 1b2a trial aims to study the safety, tolerability, and early effectiveness of this monoclonal antibody, while also understanding how the drug behaves in the body. The study focuses on patients who have high levels of circulating dipeptidyl peptidase 3 cDPP3 and require ongoing support for blood pressure and heart function. Participants are randomly assigned to receive either invobenitug or a placebo. The dose of invobenitug is 10 mg per kg of body weight. The trial is designed as a multi-center, double-blind, placebo-controlled study to carefully compare the effects of the drug against placebo. Treatments are given under close medical supervision, with researchers monitoring how the drug affects cDPP3 levels and activity to help determine the best dose for future studies. Throughout the study, participants are closely observed for any adverse effects from the treatment for up to 30 days after receiving invobenitug. Researchers measure the number of treatment-related side effects and track how the drug is processed in the blood over time. They also assess changes in cDPP3 concentration and activity. The study collects detailed safety and laboratory data to understand how the drug works and to ensure participant safety during the trial period, which lasts until the last follow-up visit at around 30 days after treatment.

Age: 18Years - 80YearsAll GendersPhase 1Phase 2
37 locations
S

Actively Recruiting

Geographic Atrophy GA is an advanced form of age-related macular degeneration AMD that causes loss of light-sensitive cells in the retina, leading to severe vision loss when the central area fovea is affected. This trial investigates whether GAL-101, given as eye drops, can slow the growth of GA and prevent it from reaching the fovea in patients with non-foveal GA secondary to non-neovascular AMD. Participants will be randomly assigned to receive either GAL-101 eye drops or placebo drops without the active drug. During clinic visits, patients will apply three doses of one drop each at 5-minute intervals under supervision. Outside visits, patients will self-administer two doses daily at 5-minute intervals. The treatment period lasts from 12 to 24 months depending on randomization, with scheduled visits for safety and efficacy assessments at baseline, 2 weeks by phone, and at 1, 3, 6, 9, and 12 months, then every 3 months until the last patient completes 12 months of treatment. Participants will attend regular clinic visits for imaging and vision tests to assess changes in GA lesion size and photoreceptor degeneration. The study uses imaging and vision charts to monitor eye health and drug effects over time. Safety assessments and adherence checks will be part of these visits. The total participation duration varies but includes at least 12 months of treatment and follow-up until study completion, expected in 2027.

Age: 55Years +All GendersPhase 2
24 locations
P

Actively Recruiting

Researchers are evaluating the treatment of anemia in patients with chronic kidney disease CKD who are on hemodialysis. This Phase III, investigator-blinded, randomized, multicenter study compares two drugs, efepoetin alfa and darbepoetin alfa, to see how well they maintain hemoglobin levels in these patients. The study aims to maintain hemoglobin between 10.0 gdL and 12.0 gdL, which is important for managing anemia in CKD. Participants will be randomly assigned in a 21 ratio to receive either efepoetin alfa or darbepoetin alfa. Both drugs are given by intravenous injection, typically after dialysis sessions. Efepoetin alfa is administered weekly from Day 1 to Week 28, with possible interval changes to one or two weeks from Week 29 to Week 52 based on investigator judgment. The study consists of three periods screening up to 28 days, treatment about 52 weeks, and a 4-week follow-up with phone contacts up to Week 56 or the last visit. During the study, participants will undergo regular assessments including hemoglobin level monitoring to evaluate the mean change between Week 20 and Week 28. Safety and efficacy are closely observed, with dosages adjusted to maintain target hemoglobin levels. Follow-up will include phone contacts to monitor participants up to Week 56. The total participation duration is approximately one year, starting from screening through treatment and follow-up.

Age: 18Years +All GendersPhase 3
58 locations
A

Actively Recruiting

Researchers are conducting a nationwide registry in Armenia to observe and track systemic autoimmune and autoinflammatory diseases. These diseases involve abnormal immune system activity causing widespread inflammation and organ damage, often influenced by genetics and environmental factors. The study aims to better understand disease progression, which is usually measured by specific activity scores, and to gather detailed epidemiological and clinical data, as current knowledge in Armenia is limited. The study involves usual medical care for patients diagnosed with these systemic diseases, alongside collecting additional blood and stool samples for biobanking. Data collected include clinical exams, lab results, current treatments, and disease-specific activity scores reported by both patients and physicians. This observational registry will continue for about five years, assessing disease manifestations and evolution under treatment. Participants will be regularly evaluated through clinical and laboratory assessments, with data recorded on disease activity and progression. The study monitors systemic symptoms and uses disease-specific scores to track changes over time. Researchers will identify rare clinical forms and prognostic factors. The registry includes informed consent procedures and follows patients longitudinally to improve understanding of these complex diseases and their management.

All AgesAll Genders
6 locations
B

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the drug balstilimab in adults with relapsed or refractory lymphomas, specifically classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma. This open-label phase 2 study focuses on patients who have no available standard therapy or have not responded to previous treatments. The study aims to gather important information about this treatment option under the guidance of the Immune Oncology Research Institute. Participants will receive balstilimab at a dose of 300 mg given intravenously every three weeks using an infusion pump. The treatment period can last up to 24 months or until certain criteria require stopping the drug or withdrawal from the study. The study includes a screening period of about 28 days before treatment and a follow-up period of up to 24 months after the last dose for those still living. During the study, participants will have regular assessments to monitor their response to treatment and safety. Researchers will measure outcomes like the objective response rate, duration of response, disease control, progression-free survival, and overall survival for up to 48 months. Safety will be closely monitored through tracking adverse events and laboratory tests. The total time a participant may be involved in the study can be approximately 49 months across all study periods.

Age: 18Years +All GendersPhase 2
1 location
I

Actively Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN is a very rare blood cancer with no agreed-upon best treatment. Researchers are working internationally to gather detailed information on how BPDCN presents, how it is diagnosed, the treatments patients receive, and their outcomes. The study aims to build a large database to better understand the disease and to develop treatment recommendations based on collected data. This study is an international registry collecting information from multiple centers about patients diagnosed with BPDCN. It includes both retrospective and prospective data from patients worldwide. The data collected covers patient details, disease characteristics, treatment information, outcomes, causes of death, and the conclusion of data collection. Consent will be obtained from prospective patients, and quality control is managed by the Immune Oncology Research Institute. Participants will provide information through questionnaires completed by their treatment centers. Researchers will analyze overall survival, complete remission rates, duration of first remission, and event-free survival over five years. This observational study does not involve treatment but gathers and monitors detailed clinical data to improve understanding and guide future therapies for BPDCN.

All AgesAll Genders
22 locations
I

Actively Recruiting

Primary cardiac angiosarcomas are very aggressive tumors that develop in the hearts blood vessel lining, making up about 25%-30% of all primary heart cancers. This cancer mainly affects the right side of the heart and is known for rapid growth and damage to healthy heart tissue. The condition has a very low five-year survival rate of around 14%, and familial forms result in even shorter survival times. The goal of this international registry is to create a large database to better understand this rare and deadly disease by collecting detailed patient and treatment information from around the world. The registry collects clinical data including patient demographics, tumor details, treatments such as surgery, chemotherapy, immunotherapy, and radiation, as well as outcomes and side effects. It aims to analyze genetic, environmental, and lifestyle risk factors, evaluate treatment effectiveness, and develop guidelines for prevention, diagnosis, and management. Data quality and management are overseen by the Immune Oncology Research Institute. Participants provide information through questionnaires about their medical history, diagnosis, treatment, complications, and follow-up outcomes. Researchers will monitor survival and disease progression over time, focusing on measures such as 6-month overall survival and longer-term remission rates. The registry promotes collaboration among international healthcare providers and helps guide future clinical trials and treatment advances for cardiac angiosarcoma. The study is planned to run until May 2035.

All AgesAll Genders
1 location
I

Actively Recruiting

Cancer is a major cause of illness and death among children, adolescents, and young adults CAYAs, particularly in low- and middle-income countries LMICs where access to timely diagnosis and treatment is often limited. This prospective, multicenter observational study follows CAYAs with cancer receiving routine care at participating hospitals in LMICs, aiming to better understand treatment outcomes and challenges faced by patients and families. Participants receive standard medical care as provided by their local hospitals without experimental treatments or changes to their treatment plans. The study observes a single group of patients over time to collect information from medical records and questionnaires focusing on access to care and social factors impacting treatment. The study covers a follow-up period extending up to 36 months after enrollment. During the study, researchers will gather data on clinical outcomes, treatment complications, interruptions, and social factors affecting care. Data collection includes medical record reviews and patient or family questionnaires. The study aims to provide valuable information to help improve cancer care and outcomes in resource-limited settings, with total participant engagement lasting up to three years.

Age: 0Years - 21YearsAll Genders
6 locations
I

Actively Recruiting

This research aims to evaluate cancer treatment outcomes among children, adolescents, and young adults aged 0 to 21 years living in low- and middle-income countries LMICs. It focuses on acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LBL, conditions where treatment success varies widely between high-income and LMICs due to factors like delayed diagnosis and limited access to quality care. The study seeks to inform future efforts to improve cancer care and reduce treatment failures in these regions. The study involves a retrospective review of medical records from participating oncology centers in countries including Guatemala, Honduras, El Salvador, Armenia, and Tanzania. It includes patients with any type of cancer diagnosis who received substantial anti-cancer treatment such as chemotherapy, surgery, radiation, or immunotherapy. Special attention is given to patients with ALL or LBL to assess therapy-related toxicities and treatment outcomes over a three-year follow-up period. Participants medical records will be analyzed to estimate the incidence of treatment failure, including relapse or progression, and therapy-related severe toxicities. Data on event-free survival and overall survival will also be collected. No experimental treatments are administered, as this is a purely observational study. The study period covers up to three years from each patients cancer diagnosis, using existing health data to better understand treatment challenges and outcomes in LMICs.

Age: 0Years - 21YearsAll Genders
7 locations

1-10 of 29

1